Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS (VRTX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Vertex Pharmaceuticals : to Announce First Quarter 2018 Financial Results on April 26

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/23/2018 | 10:34am CEST

BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close.

The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the 'Investors' section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston'sInnovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada and Australia. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for eight years in a row.

Contact:

Michael Partridge

Tel: 617-341-6108

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS
10:34aVERTEX PHARMACEUTICALS : to Announce First Quarter 2018 Financial Results on Apr..
AQ
04/17VERTEX PHARMACEUTICALS : to Announce First Quarter 2018 Financial Results on Apr..
BU
04/10VERTEX PHARMACEUTICALS : Mass. governor defends Vertex drug pricing, saying inno..
AQ
04/09VERTEX PHARMACEUTICALS : New York to consider further Medicaid rebates on Orkamb..
AQ
04/03VERTEX PHARMACEUTICALS : Appoints Kimberly A. White as Senior Vice President and..
AQ
03/29VERTEX PHARMACEUTICALS : Appoints Kimberly A. White as Senior Vice President and..
BU
03/20VERTEX PHARMACEUTICALS : MPs call on U.K. government to resolve Orkambi impasse
AQ
03/13MANAGEMENT TRACKS : WuXi NextCode, Assembly
AQ
03/12VERTEX PHARMACEUTICALS : to Present at the Cowen Healthcare Conference on March ..
BU
03/06VERTEX PHARMACEUTICALS : U.K. Parliament to debate NHS access for Vertex's Orkam..
AQ
More news
News from SeekingAlpha
04/20Key events next week - healthcare 
04/14VENTURE CAPITAL DEALS OF THE WEEK : Tencent Led $3B Investment 
04/13Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned 
04/09THE BIO-TECH 'WRECK' : General, And Company-Specific Analysis 
04/06Goldman bullish on CRISPR Therapeutics, seeks 
Financials ($)
Sales 2018 2 791 M
EBIT 2018 792 M
Net income 2018 444 M
Finance 2018 2 398 M
Yield 2018 -
P/E ratio 2018 90,70
P/E ratio 2019 47,04
EV / Sales 2018 13,5x
EV / Sales 2019 10,7x
Capitalization 40 153 M
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 192 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS5.53%40 153
GILEAD SCIENCES2.88%96 094
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998
BLUEBIRD BIO INC-4.27%8 522